Search

This paper presents the results of a study of the characteristics of phase synchronization between electrocardiography(ECG) and electroencephalography (EEG) signals during night sleep. Polysomnographic recordings of eight generally healthy subjects and eight patients with obstructive sleep apnea syndrome were selected as experimental data. A feature of this study was the introduction of an instantaneous phase for EEG and ECG signals using a continuous wavelet transform at the heart rate frequency using the concept of time scale synchronization, which eliminated the emergence of asynchronous areas of behavior associated with the "leaving" of the fundamental frequency of the cardiovascular system. Instantaneous phase differences were examined for various pairs of EEG and ECG signals during night sleep, and it was shown that in all cases the phase difference exhibited intermittency. Laminar areas of behavior are intervals of phase synchronization, i.e., phase capture. Turbulent intervals are phase jumps of 2 π. Statistical studies of the observed intermittent behavior were carried out, namely, distributions of the duration of laminar sections of behavior were estimated. For all pairs of channels, the duration of laminar phases obeyed an exponential law. Based on the analysis of the movement of the phase trajectory on a rotating plane at the moment of detection of the turbulent phase, it was established that in this case the eyelet intermittency was observed. There was no connection between the statistical characteristics of laminar phase distributions for intermittent behavior and the characteristics of night breathing disorders (apnea syndrome). It was found that changes in statistical characteristics in the phase synchronization of EEG and ECG signals were correlated with blood pressure at the time of signal recording in the subjects, which is an interesting effect that requires further research. [ABSTRACT FROM AUTHOR]

Hannu Uusitalo,1 Evgeniy Egorov,2 Kai Kaarniranta,3 Yuri Astakhov,4 Auli Ropo5 On behalf of the Switch Study Tafluprost Study Groups 1Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; 2Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russia; 3Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland, 4Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russia, 5Global Medical Affairs, Santen Oy, Tampere, Finland Introduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface disease while using preserved latanoprost eye drops benefited from switching to preservative-free tafluprost eye drops. Patients and methods: The analysis was based on 339 glaucoma patients enrolled in two Phase IIIb trials. The patients were required to have two symptoms, or one sign and one symptom of ocular surface disease at baseline, and at least 6 months preceding treatment with latanoprost eye drops preserved with benzalkonium chloride. All eligible patients were switched from latanoprost to preservative-free tafluprost for a total of 12 weeks. Ocular symptoms and ocular signs were evaluated at baseline and at 2 weeks, 6 weeks, and 12 weeks after commencing treatment with tafluprost. Intraocular pressure (IOP), drop discomfort, and treatment preference were evaluated to investigate the clinical efficacy and patient-related outcomes. Results: After 12 weeks of treatment with preservative-free tafluprost, the incidences of irritation/burning/stinging, foreign body sensation, tearing, itching, and dry eye sensation had diminished to one-third of those reported for preserved latanoprost at baseline. The incidences of blepharitis and corneal/conjunctival fluorescein staining had in turn decreased to one-half of those reported for preserved latanoprost. Severity of conjunctival hyperemia was halved during treatment with preservative-free tafluprost, and there was significant improvement in tear break-up time and tear production. A further reduction in IOP (~1 mmHg) was seen with preservative-free tafluprost compared with preserved latanoprost. Drop discomfort was alleviated during preservative-free tafluprost treatment, and an outstanding majority of patients (72%) preferred preservative-free tafluprost over preserved latanoprost. Conclusion: This meta-analysis confirmed that IOP remained at the same level after replacing benzalkonium chloride-preserved latanoprost eye drops with preservative-free tafluprost eye drops. Preservative-free tafluprost significantly decreased the symptoms and signs of ocular surface disease and outrated latanoprost in drop comfort and treatment preference. Keywords: Taflotan®, preserved latanoprost, Xalatan®, ocular surface disease, ocular symptoms and signs, IOP, patient-related outcome